Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth r ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Global partners have supported Africa’s progress in HIV vaccine research and development. Organisations such as the US ...

(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...